#294 Real World Evidence for COVID-19 Vaccines
CLINICAL QUESTION
What is the real-world effectiveness for currently available COVID-19 vaccines?
BOTTOM LINE
Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- From relatively short cohort/case-control studies or registries. Fully vaccinated defined as 7- or 14-days post-second dose.
- Israel national vaccination (Pfizer) program of 6.5 million adults ≥16 years old.1 New COVID-19 cases in the program’s initial 10 weeks was compared to vaccine status. Full vaccination decreased risk of:
- All COVID-19 infections: By 97%.
- Hospitalizations and deaths: By 98% and 99% respectively.
- Limitations: The same individuals contributed time to unvaccinated, partially vaccinated and fully vaccinated calculations.
- United Kingdom case-control study, persons ≥70 years with COVID-19 (n=44,590) linked to vaccine status.2 Single dose of either Pfizer or AstraZeneca reduced:
- Symptomatic infections: ~60% (~1 month after either vaccine).
- Hospitalizations: 80% (either vaccine).
- Death: ~85% [Pfizer (AstraZeneca death rates not reported)].
- Ontario four-month case-control study, adults ≥16 years:3
- Single-dose (Pfizer or Moderna) reduced:
- Symptomatic infection: 60%.
- Hospitalization or death: 70%.
- Two-doses reduced:
- Symptomatic infection: 91%.
- Hospitalization or death: 98%.
- Single-dose (Pfizer or Moderna) reduced:
- Findings similar to clinical trials.4
- Variants of Concern (VOC):
- Two doses of Pfizer or AstraZeneca reduces symptomatic delta variant infections or hospitalizations similar to non-VOC infections.5
- Pfizer or Moderna vaccination reduces symptomatic infection or hospitalizations in four current VOC (alpha, beta/gamma, delta) similar to non-VOC.6
- Two doses are better than one.6
- Safety in Pregnancy:
- 35,691 pregnant women received Pfizer or Moderna vaccine (29% 1st trimester, 43% second trimester, 26% third trimester):7
- Adverse pregnancy outcomes with vaccine same as baseline risk.7
- Babies born to pregnant women with COVID-19 are twice as likely to develop severe perinatal morbidity and mortality.8
- Pregnant women with COVID-19 have 50% greater risk of maternal morbidity or mortality.8
- 35,691 pregnant women received Pfizer or Moderna vaccine (29% 1st trimester, 43% second trimester, 26% third trimester):7
- Pregnant women should be offered COVID-19 vaccine.9
- Recommendations for vaccinated individuals available: Canada or United States.10,11
Latest Tools for Practice
#384 Treatment of PTSD Nightmares: Is prazosin a dream come true?
How effective is prazosin for nightmares in posttraumatic stress disorder (PTSD)?
#383 A single dose for treating yeast infections: Is it really this simple?
Does route or duration of antifungals matter when treating uncomplicated vulvovaginal candidiasis in non-pregnant women?
#382 Exercise for Parkinson’s Disease: More movement = Better movement?
How effective is exercise in Parkinson’s disease?
Good info
Good
Good review
confirms knowledge
no number of patients in evidence
Very helpful information in backing up the argument that the covid vaccine was very effective and safe